JOURNAL OF NEPHROLOGY is a premier academic journal dedicated to the field of nephrology, published by Springer Heidelberg. With its ISSN 1121-8428 and E-ISSN 1724-6059, this journal serves as a dynamic platform for disseminating high-quality research and groundbreaking findings in kidney health and disease. Since its inception in 1989, it has established itself as a vital resource for professionals, researchers, and students, consistently ranking in the top quartile (Q1) of nephrology journals and securing an impressive Scopus rank of #19 out of 81, placing it in the 77th percentile. Although it operates under a subscription model, the journal fosters an inclusive academic environment where critical discussions and innovative approaches to nephrological challenges are encouraged. With a commitment to advancing knowledge and practice in nephrology, JOURNAL OF NEPHROLOGY remains an essential resource for anyone who seeks to stay at the forefront of kidney research and clinical care.

RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.

ZEITSCHRIFT FUR RHEUMATOLOGIE, published by Springer Heidelberg, serves as a vital platform in the field of rheumatology, providing researchers, clinicians, and students with cutting-edge findings and discussions related to the diagnosis, treatment, and management of rheumatic diseases. Since its inception in 1974 and continuing until 2024, this journal retains its commitment to disseminating significant scientific work within this specialized domain. Although it is currently categorized in the Q4 quartile for Rheumatology and ranks 47 out of 73 in Scopus, reflecting its burgeoning presence, the journal is dedicated to evolving and gaining prominence in the academic community. By offering valuable insights and fostering scholarly discourse, ZEITSCHRIFT FUR RHEUMATOLOGIE plays a crucial role in advancing rheumatology research and enhancing patient care practices worldwide. The journal presents an opportunity for its readers to engage with contemporary studies and enrich their understanding of rheumatic ailments.

LUPUS is a premier peer-reviewed journal published by SAGE Publications Ltd, focusing on the field of rheumatology, with a specific emphasis on the complexities of lupus and related autoimmune disorders. Since its inception in 1991, the journal has consistently ranked in the Q2 category within the rheumatology field, currently positioned as #29 out of 73 in Scopus, reflecting its significant contributions to research and clinical practice. The journal aims to foster a deeper understanding of lupus through the publication of original research articles, reviews, and clinical studies, making it an essential resource for researchers, clinicians, and students dedicated to advancing knowledge in this vital area of medicine. With an impact factor that underscores its influence, LUPUS serves as a critical platform for sharing innovative findings and engaging discussions within the global scientific community. Although the journal follows a traditional access model, it is situated in the United Kingdom, at 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England, and remains dedicated to supporting the continuous advancement of research in autoimmune diseases.

Arthritis & Rheumatology is a leading journal dedicated to the advancement of knowledge in the fields of rheumatology, immunology, and allergy. Published by WILEY in the United Kingdom, this prestigious journal boasts an impressive impact factor and a prominent reputation, ranking in the Q1 category across multiple disciplines, including Immunology and Rheumatology. With its high ranking of 4th out of 73 in Rheumatology and notable standings in related fields, it serves as a crucial platform for researchers, healthcare professionals, and scholars to disseminate groundbreaking findings. The journal embraces an Open Access model, enhancing the accessibility of vital research to a global audience and ensuring that knowledge dissemination is maximized. Since its inception in 2014, Arthritis & Rheumatology has been at the forefront of impactful research, fostering collaboration and innovation in tackling complex challenges within these medical disciplines. Researchers looking to explore the latest advancements and engage with cutting-edge studies in these fields will find this journal to be an essential resource.

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, published by Elsevier, stands as a premier journal in the field of rheumatology, holding a prestigious Q1 ranking in both Medicine (miscellaneous) and Rheumatology categories as of 2023. With an ISSN of 1521-6942 and an E-ISSN of 1521-1770, the journal is dedicated to advancing clinical knowledge and practice through the dissemination of high-quality, peer-reviewed research. Since its inception in 1995, this journal has provided a platform for researchers, clinicians, and healthcare providers to share significant advancements, best practices, and innovative insights that shape the standards of care in rheumatology. The commitment to open access publishing reflects its mission to broaden the reach of critical research findings, ensuring that professionals across the globe can access valuable information in this vital field. The journal's impressive Scopus ranking, positioned at #10 out of 73 in Medicine-Rheumatology, alongside its notable impact factor, underscores its importance and influence in guiding clinical practice and policy in rheumatologic conditions. By engaging with this journal, readers can stay informed about emerging trends and evidence-based strategies that are crucial for improving patient outcomes.

Rheumatic Disease Clinics of North America is a premier journal published by W B Saunders Co-Elsevier Inc, dedicated to advancing the field of rheumatology through comprehensive and impactful research. With an ISSN of 0889-857X and an E-ISSN of 1558-3163, this esteemed publication has been disseminating knowledge since its inception in 1987, and continues to guide clinicians and researchers alike through its insightful articles and case studies. Positioned in the 2023 Q2 quartile for Rheumatology, it ranks #31 out of 73 journals in the Scopus category of Medicine _ Rheumatology, reflecting a commendable impact factor and relevance in the academic community. Although it does not offer open access options, the journal ensures that subscribers have access to cutting-edge research and reviews that address contemporary challenges and advancements in rheumatic disease. With its authoritative content, Rheumatic Disease Clinics of North America serves as a vital resource for those striving to improve patient care and clinical outcomes in the ever-evolving landscape of rheumatology research.

Current Opinion in Rheumatology, published by Lippincott Williams & Wilkins, stands as a vital resource in the field of rheumatology. Since its inception in 1989, this prestigious journal has been at the forefront of disseminating cutting-edge research, with a notable Q1 ranking in the 2023 Rheumatology category and an impressive Scopus rank of 7 out of 73, placing it in the 91st percentile. The journal's commitment to presenting insightful reviews and critical analyses of recent advancements and treatment strategies makes it an essential read for professionals, researchers, and students dedicated to the study of rheumatic diseases. Although not an open-access journal, Current Opinion in Rheumatology continues to foster an informed dialogue within the academic community through its high-impact content, ensuring that the latest developments and practices are accessible to those at the vanguard of rheumatology research.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.